Lenalidomide (CC-5013)

For research use only.

Catalog No.S1029

83 publications

Lenalidomide (CC-5013) Chemical Structure

Molecular Weight(MW): 259.26

Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 70 In stock
USD 147 In stock
USD 407 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Lenalidomide (CC-5013) has been cited by 83 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Lenalidomide (CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.
Targets
TNF-α [1]
(PBMCs)
13 nM
In vitro

Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LB771-HNC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLYXmxXUUN3ME2yMlE2ODN6IN88US=> M374b3NCVkeHUh?=
L-363 NHzvbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HpbGlEPTB;Mj65NlIyOiEQvF2= MW\TRW5ITVJ?
JAR M3\PdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XLV2lEPTB;Mj65O|AxOSEQvF2= NEPMU|FUSU6JRWK=
EoL-1-cell MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDpRmxKSzVyPUSuNVA2OTVizszN MnuyV2FPT0WU
BT-549 NIrLWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LjeWlEPTB;Nj6yNVg1QSEQvF2= M1zMfXNCVkeHUh?=
SK-NEP-1 NGrneFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETET|JKSzVyPUeuPFk2OTJizszN MUHTRW5ITVJ?
BV-173 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRThwNke1PFUh|ryP NF;OUpRUSU6JRWK=
HMV-II NUPGemZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H5NmlEPTB;MUCuNFE4OiEQvF2= NVLYeFVJW0GQR1XS
HCC1806 NVu4cVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fxdmlEPTB;MUGuOFQ3PyEQvF2= MnrrV2FPT0WU
KASUMI-1 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;2TWM2OD1zMT61O|Eh|ryP NWm0TpF7W0GQR1XS
SK-MEL-28 NYXKRmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGwTWM2OD1zMT65O|Y1KM7:TR?= M{nTc3NCVkeHUh?=
RPMI-8226 NFjuTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF{Lk[yOFEh|ryP MWXTRW5ITVJ?
T47D M4jUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF|LkKwPVkh|ryP M{TsR3NCVkeHUh?=
HOP-62 NX3FcWp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLMTWM2OD1zMz60PEDPxE1? NWD2S4g2W0GQR1XS
A2058 M1nacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPOcFRKSzVyPUGzMlgyQTlizszN NF74TWpUSU6JRWK=
SW620 NG[xWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF2LkK0O|Mh|ryP MkXQV2FPT0WU
LCLC-103H Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF2LkS4PVIh|ryP NVny[oo3W0GQR1XS
HAL-01 M2XKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorxTWM2OD1zND61O|k3KM7:TR?= NY\G[5VsW0GQR1XS
PANC-08-13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF2LkmxNFgh|ryP NH\xbo9USU6JRWK=
COLO-684 M1m5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7oTWM2OD1zNT6zPVc6KM7:TR?= NFPFW2hUSU6JRWK=
DEL M4\tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF3LkS5PUDPxE1? MV;TRW5ITVJ?
K5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDoVlZKSzVyPUG2MlE1QDZizszN NFi3bIFUSU6JRWK=
SK-MEL-24 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XHRWlEPTB;MU[uOFY2OiEQvF2= NGnuT5RUSU6JRWK=
ACN MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF4LkWyPVch|ryP MonOV2FPT0WU
H9 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLHTWM2OD1zNj62NlYh|ryP NGezZlZUSU6JRWK=
EM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF5LkG0N{DPxE1? MUjTRW5ITVJ?
HSC-4 Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF5Lk[2NFEh|ryP M2HQWHNCVkeHUh?=
IGROV-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\ZTWM2OD1zNz63PFMh|ryP NXzrN3FXW0GQR1XS
TE-1 M1XSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7XTWM2OD1zNz65PVY5KM7:TR?= NHrQVWJUSU6JRWK=
LN-405 NYPjbGZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnjS|ZtUUN3ME2xPU46ODd4IN88US=> M3\3dXNCVkeHUh?=
MSTO-211H NIHoNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJyLkO1O|Mh|ryP MkTUV2FPT0WU
MOLT-4 NYPSXJZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\JV2hKUUN3ME2yNE42PzV7IN88US=> NHL2OpRUSU6JRWK=
RS4-11 NXTk[GZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T6fmlEPTB;MkKuNVU3OyEQvF2= NFfP[pFUSU6JRWK=
ES3 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjMTmZKSzVyPUKyMlY6PjNizszN NXfncXdpW0GQR1XS
SBC-1 M2PuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XvSGlEPTB;MkOuPFY6PiEQvF2= MlroV2FPT0WU
CTV-1 NUX2b4V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPwT5ZKSzVyPUK1MlAyPDlizszN NVrkW3p{W0GQR1XS
HuP-T3 M3L4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzMTWM2OD1{NT60NFA6KM7:TR?= NFi0XXpUSU6JRWK=
HCC2218 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PBO2lEPTB;MkWuOVQxPyEQvF2= MWXTRW5ITVJ?
HDLM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJ6LkKwNlYh|ryP NFjoW3RUSU6JRWK=
ABC-1 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3hc2ZKSzVyPUK5MlY6PzRizszN NXfCNFNIW0GQR1XS
MV-4-11 M37UXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC4dm1KSzVyPUK5Mlc{OTdizszN NX2wSWFTW0GQR1XS
WM-115 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrxOHNKSzVyPUOwMlMxQTlizszN NV\2b4k3W0GQR1XS
SW1990 M36yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmzOlNKSzVyPUOwMlM{KM7:TR?= MmHCV2FPT0WU
HCC70 NIXxOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNyLkezOFYh|ryP M1zRRXNCVkeHUh?=
KYSE-520 MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNyLki4N|kh|ryP NG\kT2lUSU6JRWK=
JEG-3 NGfpSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WxSmlEPTB;M{GuNVYyPCEQvF2= M13j[XNCVkeHUh?=
C8166 M{LUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHvfINwUUN3ME2zNU4zOjd2IN88US=> MVfTRW5ITVJ?
SK-OV-3 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HNS2lEPTB;M{GuOlc2PSEQvF2= NVvtPFg4W0GQR1XS
NCI-H526 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITxR4xKSzVyPUOyMlY5OyEQvF2= MYjTRW5ITVJ?
NKM-1 NIrLOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrJblJKSzVyPUOyMlk2PjhizszN NH20THNUSU6JRWK=
ECC10 NGK2eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrrT3JXUUN3ME2zOE44PDR|IN88US=> NUi3W|ZHW0GQR1XS
A2780 M1zYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDDTWM2OD1|NT6zOlAyKM7:TR?= NEPWeotUSU6JRWK=
KY821 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq3OlQ1UUN3ME2zOU44PjhzIN88US=> Mn\aV2FPT0WU
MKN1 NUO1dGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN4LkKxN|ch|ryP MVvTRW5ITVJ?
EKVX NUTlb2tbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTN5LkSyNVIh|ryP NWHVOZZtW0GQR1XS
EW-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN6LkO4PFUh|ryP NGri[I5USU6JRWK=
CTB-1 NGLFR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\3TWM2OD1|OT63O|g6KM7:TR?= M4nSXXNCVkeHUh?=
COR-L105 NVS2TZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS3TWM2OD12MD60O|Q3KM7:TR?= MnfVV2FPT0WU
NCI-SNU-5 NULmSlBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTRzLkKwOlkh|ryP NU\rdYdoW0GQR1XS
Mewo MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTRzLkm4O|Eh|ryP NVvoO4J3W0GQR1XS
BCPAP NYHmN3A{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj1TohSUUN3ME20N{44QTF5IN88US=> NVLOSHFzW0GQR1XS
KARPAS-45 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TWd2lEPTB;NESuNlc4PiEQvF2= MWPTRW5ITVJ?
NCI-H1693 M1nQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPJTWM2OD12Nj62PVg3KM7:TR?= NGPvRWNUSU6JRWK=
H-EMC-SS M1XaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljyTWM2OD12OD6zNlI1KM7:TR?= NFLIU|NUSU6JRWK=
697 M1:0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH5dIxIUUN3ME21NE4{PTR3IN88US=> MXfTRW5ITVJ?
KP-N-YS NUHMV|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3zXmhOUUN3ME21Nk4{OTR{IN88US=> NUfHdVVPW0GQR1XS
NCI-H1304 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH4bVJZUUN3ME21Nk44ODJ2IN88US=> MUHTRW5ITVJ?
NOS-1 M4jETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTV{Lki1OVkh|ryP M1nqZnNCVkeHUh?=
NCI-H2342 M2jzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:5WWlEPTB;NUOuNFUxQCEQvF2= M2TqbHNCVkeHUh?=
KYSE-270 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq0VoVVUUN3ME21N{43OzZ2IN88US=> NUDuXXVSW0GQR1XS
LU-135 NVzifW8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTV3LkG4OVMh|ryP Mk\OV2FPT0WU
OE33 NXH1XGpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTV3LkixPEDPxE1? NWHXb3N4W0GQR1XS
ML-2 M4rjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG3bmF1UUN3ME21OU46PDh7IN88US=> M{SxXXNCVkeHUh?=
KMOE-2 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfEfXBKSzVyPUW2MlI5QTNizszN NEOwdJBUSU6JRWK=
Daoy M1:2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH6NI57UUN3ME21Ok4{OjB2IN88US=> MkPhV2FPT0WU
KNS-62 M3vrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTV5LkCxOFIh|ryP M4nib3NCVkeHUh?=
NBsusSR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL0RYVOUUN3ME21O{42PzB3IN88US=> NUXFcHR{W0GQR1XS
UACC-257 M4eyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjO[2tKSzVyPUW4MlYzPjRizszN MYHTRW5ITVJ?
LU-139 NVnqOHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTV6LkiyOkDPxE1? NX3xbGpNW0GQR1XS
CAL-85-1 NVrL[2FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrLTWM2OD13OD64OlQ{KM7:TR?= NULCNlNPW0GQR1XS
NCI-H720 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\ENI1DUUN3ME21PE45QTR{IN88US=> M3HESnNCVkeHUh?=
MLMA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTV7LkC5NUDPxE1? MVXTRW5ITVJ?
A3-KAW M1O0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG2WYNKSzVyPUW5MlI5ODlizszN M4XVOHNCVkeHUh?=
Ramos-2G6-4C10 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLOTWM2OD13OT62Nlg4KM7:TR?= NFvNd4xUSU6JRWK=
A388 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\mdWdKSzVyPU[wMlQ1QSEQvF2= NUHjfWlLW0GQR1XS
LAMA-84 NHPGVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HQfmlEPTB;NkCuPVkxPSEQvF2= NWrXeFdOW0GQR1XS
GCT M4f5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;PTWM2OD14MT6wO|g3KM7:TR?= MnfXV2FPT0WU
K-562 NVvCeoNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTZzLkWzN|Mh|ryP M3fIfXNCVkeHUh?=
NCI-H1666 MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S2dmlEPTB;NkGuPFc2KM7:TR?= NXPNUo9DW0GQR1XS
NCI-H1993 M1S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPSfm1KSzVyPU[zMlQxPDNizszN NXTkd3k4W0GQR1XS
NCI-H358 NFn2e4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTZ3LkCxNlEh|ryP NUnXNY1mW0GQR1XS
NB6 NXLwR|dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTZ3Lkm4PEDPxE1? MX7TRW5ITVJ?
HCE-T NXLLcWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXhXpJKSzVyPU[3MlA4QThizszN NF7GTWdUSU6JRWK=
DOK NUDB[|Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3xZpFKSzVyPU[3MlQ6PDhizszN M3HF[3NCVkeHUh?=
HT-1376 M1TQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\6TWM2OD14OT64N|E1KM7:TR?= MVTTRW5ITVJ?
NEC8 M1S0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Ts[mlEPTB;N{CuNVI1OyEQvF2= M{PrNHNCVkeHUh?=
G-402 M2iyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XzOGlEPTB;N{CuPVM6PSEQvF2= MmDNV2FPT0WU
GR-ST MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLRTWM2OD15MT6xO|Ih|ryP NETHbmZUSU6JRWK=
QIMR-WIL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPUTWM2OD15MT60OFM1KM7:TR?= NVf6dXdbW0GQR1XS
CHP-212 NYXkZY85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q2R2lEPTB;N{GuPVY2KM7:TR?= M2jUUXNCVkeHUh?=
KU812 M3fDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W3XWlEPTB;N{KuPVcxOiEQvF2= NFfHfIJUSU6JRWK=
Becker Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfYdog5UUN3ME23N{4yPDh7IN88US=> MnHVV2FPT0WU
ChaGo-K-1 NXrsSJhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTHZXBKSzVyPUe0Mlc1QDZizszN MX;TRW5ITVJ?
A498 NHf0elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHncYIyUUN3ME23OE46OzB6IN88US=> NHK4THJUSU6JRWK=
NCI-H69 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm5dWFKSzVyPUe1Mlc3PjNizszN MUTTRW5ITVJ?
NCI-H209 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTDeYtKSzVyPUe4MlYyPDdizszN NITPeZpUSU6JRWK=
CAL-33 NGX3S4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT4W2RKSzVyPUe4Mlk6OzlizszN M{j3U3NCVkeHUh?=
COLO-680N MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPMSlV2UUN3ME23PU4yODB5IN88US=> NVHmcFE2W0GQR1XS
D-283MED NX;4b2pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WzXWlEPTB;N{muPFEzKM7:TR?= NIO4NJpUSU6JRWK=
ATN-1 NXzEe2F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL1V3VKSzVyPUixMlEyQDdizszN M3rQVHNCVkeHUh?=
NCI-N87 NWHzXYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrB[GtbUUN3ME24NU44Ojl4IN88US=> MVjTRW5ITVJ?
MHH-NB-11 MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILiNWdKSzVyPUixMlg5PDlizszN NXi1U5BXW0GQR1XS
HEL NV3QU4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHiWYw6UUN3ME24Nk41OTN2IN88US=> MW\TRW5ITVJ?
NB69 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD4XmVXUUN3ME24N{4xODN|IN88US=> NV20RpE5W0GQR1XS
MPP-89 NE\WOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfB[GtKSzVyPUizMlI2PzVizszN MX\TRW5ITVJ?
COLO-829 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:zeWRJUUN3ME24OU41QTF{IN88US=> NYjVWHJbW0GQR1XS
ONS-76 NWXlbmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLUVGhKSzVyPUi1Mlc6ODhizszN MVfTRW5ITVJ?
EW-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO1U5NxUUN3ME24Ok4zODN{IN88US=> MYDTRW5ITVJ?
EW-11 NXPZRWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPWWGRKSzVyPUi2MlQ{OzZizszN M3LZWnNCVkeHUh?=
SW900 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m2WGlEPTB;OEeuNlA2OyEQvF2= NUSxfHVKW0GQR1XS
MOLT-13 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTh5LkKyOFMh|ryP NYTBZ2xPW0GQR1XS
HuP-T4 M3z2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7JTWM2OD17MT6wOFA2KM7:TR?= NUDmVoJoW0GQR1XS
HCC1419 NXy3cGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3tXWVKSzVyPUmxMlY{PzRizszN M2Pu[3NCVkeHUh?=
CAL-72 NELJVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHrWJBUUUN3ME25Nk4xOjF7IN88US=> NVThPHo2W0GQR1XS
Mo-T M{H4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnyyTWM2OD17Mj63Olk4KM7:TR?= NWjnepBHW0GQR1XS
OC-314 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi5SGJyUUN3ME25Nk45QDJzIN88US=> NYq1NJc2W0GQR1XS
BHT-101 NFXq[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\FSZZKSzVyPUmzMlEh|ryP MkLIV2FPT0WU
EW-18 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTl|Lki0OlIh|ryP MXLTRW5ITVJ?
TE-12 NV;zZYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrvOWFKSzVyPUm0MlMxPTVizszN M1LvUHNCVkeHUh?=
MDA-MB-361 M3zMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS0W3FKSzVyPUm2MlA2OTZizszN M{X3VnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-IKKβ / IKKβ ; 

PubMed: 22698399     


Western blot analysis of the indicated proteins following treatment of OCI-Ly10 cells with lenalidomide (10μM) for the indicated times. 

MDM2 / p-MDM2 / p-p53 / p53 ; 

PubMed: 22525275     


(a) Treatment with lenalidomide (Len) increases phosphorylation of ser46 and thr55 of p53. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were prepared and analyzed by Western blotting with antibodies to MDM2, phospho-ser46 of p53, phospho-thr55 of p53 and total p53. (b) Treatment with lenalidomide increases phosphorylation of MDM2 at ser166 and ser186. Namalwa cells were treated with lenalidomide at various concentrations for 48 hours, the cell lysates were immunoprecipitated using anti-MDM2 antibody. The samples were separated by SDS PAGE and then Western blotted with either anti-MDM2 or antibodies specific to phospho-ser166, phospho-ser186, total phospho-serine or total phospho-threonine of MDM2 as indicated. 

22698399 22525275
Growth inhibition assay
Cell viability; 

PubMed: 22698399     


Viability (MTS assay) of ABC and GCB DLBCL cell lines treated with lenalidomide for 4 days. Error bars show the standard error of the mean (SEM) of triplicates.

22698399
In vivo The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]

Protocol

Animal Research:

[5]

- Collapse
  • Animal Models: Adult male Sprague-Dawley rats bearing HUVECs cells
  • Dosages: 50 mg/kg and 250 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (200.57 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG 300+5%Tween80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.26
Formula

C13H13N3O3

CAS No. 191732-72-6
Storage powder
in solvent
Synonyms N/A
Smiles NC1=C2CN(C3CCC(=O)NC3=O)C(=O)C2=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03660072 Not yet recruiting Other: Non-Interventional Multiple Myeloma Bristol-Myers Squibb March 31 2020 --
NCT03779555 Recruiting Other: Medication Event Monitoring System Multiple Myeloma Washington University School of Medicine|Alliance for Clinical Trials in Oncology December 13 2019 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the formulation for mouse injection(i.p.)?

  • Answer:

    This paper has the information you need: http://link.springer.com/article/10.1208/s12248-012-9401-2. Add lenalidomide to the appropriate volume of sterile phosphate-buffered saline (PBS) containing 1% hydrochloric acid (HCl). the pH of this preparation was adjusted to 7.0–7.6 using sodium hydroxide and sterile filtered using a 0.22 μm Steriflip filter.

  • Question 2:

    what is the procedure to resuspend this compound?

  • Answer:

    You can resuspend this compund by DMSO, the solubility is about 52 mg/mL (200.57 mM). For in vivo study, you can prepare the working solution with the vehicle of: 30% PEG400/0.5% Tween80/5% propylene glycol for oral administration.

E3 ligase Ligand Inhibitors with Unique Features

Tags: buy Lenalidomide (CC-5013) | Lenalidomide (CC-5013) supplier | purchase Lenalidomide (CC-5013) | Lenalidomide (CC-5013) cost | Lenalidomide (CC-5013) manufacturer | order Lenalidomide (CC-5013) | Lenalidomide (CC-5013) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID